Splice Chips

Services - Splice Chips

Splice Variant Microarrays
Description
Our bioinformatics team can come-up with the right microarray design and will do the research necessary to include oligo designs to obtain profiles for a majority of splice variants of genes relevant to your application. The variants we can include are those represented in the EST database and available in the literature. However, because of our ex-situ microarray manufacturing approach, application specific microarray elements representing novel splice variants can easily be added to any microarray. Email services@arrayit.com. Certain types of Splice variant microarrays may require a license from ExonHit.

Gilbert, W., Science, 1998. 282: p. 659-661.

Consortium, I., Initial sequencing and analysis of human genome. Nature, 2001. 409(6822): p. 860-921.

Kan Z, R.E., Gish WR, States DJ., Gene structure prediction and alternative splicing analysis using genomically aligned ESTs. Genome Res., 2001. 11(5): p. 889-900.

Johnson JM, C.J., Garrett-Engele P, Kan Z, Loerch PM, Armour CD, Santos R, Schadt EE, Stoughton R, Shoemaker DD., Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science, 2003. 302(5653): p. 2141-2144.

Graveley, B., Alternative splicing: increasing diversity in the proteomic world. Trends Genet., 2001. 17(2): p. 100-107.

Maniatis T, T.B., Alternative pre-mRNA splicing and proteome expansion in metazoans. Nature, 2002. 418(6894): p. 236-243.

Modrek B, L.C., Alternative splicing in the human, mouse and rat genomes is associated with an increased frequency of exon creation and/or loss. Nat Genet., 2003. 34(2): p. 177-180.

Garciaa-Blanco, M.A., A.P. Baraniak, and E.L. Lasda, Alternate splicing in disease and therapy. Nature Biotechnology, 2004. 22(5): p. 535-546.

Bracco, L. and J. Kearsey, The relevance of alternate splicing to pharacogenomics. Trends in Biotechnology, 2003. 21: p. 346-353.

Murphy MP, B.M., Clark LS, Cayouette M, Benson L, Morris DM, Polli JW., Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of a phase III clinical trial. Pharmacogenetics., 2000. 10(7): p. 583-590.

Stenson PD, B.E., Mort M, Phillips AD, Shiel JA, Thomas NS, Abeysinghe S, Krawczak M, Cooper DN., Human Gene Mutation Database (HGMD): 2003 update. Hum Mutat., 2003. 21(6): p. 577-581.

Hanioka N, K.S., Meyer UA, Gonzalez FJ., The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934----A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3' splice recognition site. Am J Hum Genet., 1990. 47(6): p. 994-1001.

Xu Q, L.C., Discovery of novel splice forms and functional analysis of cancer-specific alternative splicing in human expressed sequences. Nucleic Acids Res. 2003 Oct 1;31(19):5635-43., 2003. 31(19): p. 5635-5643.